The Nrf2 pathway in the progression of renal disease
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The Nrf2/Keap1 system regulates the transcription of antioxidant and cytoprotective genes through direct Nrf2 binding to responsive elements in the promoter region of target genes or via Keap1-induced NF-kB inhibition. The association between oxidative stress and inflammation with progression of chronic kidney diseases (CKDs) directed attention towards bardoxolone methyl and its analogues, potent Nrf2/Keap1 inducers, as a potential modality of renoprotective intervention. In a phase II clinical trial (BEAM), bardoxolone methyl was shown to increase the estimated glomerular filtration rate (eGFR) in patients with CKD associated with type 2 diabetes. The study generated great interest but raised concerns as well, on the adverse event profile of the drug. Experiments in rats with type 2 diabetic nephropathy treated with bardoxolone methyl analogues reproduced some drawbacks of bardoxolone methyl therapy in humans. Despite these warnings, a long-term phase III trial (BEACON) was started that was prematurely terminated because of an excess serious adverse events and mortality. Lessons from the above studies suggest that before jumping into use in clinical practice, adequately designed experiments in animal models are needed to provide insights into pathogenetic mechanisms as well as unexpected side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Cell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE Pathway
Kensler, T. W., Wakabayashi, N., & Biswal, S. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141046 · Cited by 3,630 · cited 3×
“All rights reserved. i19 detoxifying enzymes such as catalase, superoxide dismutase, haeme oxygenase-1 (HO-1), NAD(P)H:quinone oxidoreductase 1, glutathione peroxidase-2 and glutathione S-transferase [1, 2].”
BackgroundNrf2–Keap1 defines a physiologically important stress response mechanism
Motohashi, H., & Yamamoto, M. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.09.003 · Cited by 1,725 · cited 1×
“Nrf2 is normally maintained in the cytoplasm by interaction with the cytosolic repressor protein Keap1, an adaptor component of Cullin 3-based ubiquitin E3 (Cul-E3) ligase complex, which promotes ubiquitination and proteosomal degradation of Nrf2 [3, 4].”
BackgroundNrf2 is a critical regulator of the innate immune response and survival during experimental sepsis
Thimmulappa, R. K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25790 · Cited by 1,028 · cited 1×
“Thus, Nrf2-deficient mouse embryonic fibroblasts (MEFs) after stimulation with lipopolysaccharide or TNF-α had higher levels of phosphorylated IkBα and greater IKK kinase activity than Nrf2 MEFs [27].”
BackgroundWakabayashi, N., Dinkova-Kostova, A. T., Holtzclaw, W. D., Kang, M.-I., Kobayashi, A., Yamamoto, M., Kensler, T. W., & Talalay, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307301101 · Cited by 986 · cited 1×
“Exposure to both endogenous and exogenous molecules as reactive oxygen species, 15-deoxy-delta12,14-prostaglandin J2, dithiolethiones, triterpenoids, isothiocyanates, can modify reactive cysteins in Keap1 [6] and lead to dissociation of Nrf2 from the Keap1/Nrf2 complex, or induce conformational changes in Keap1 rescui…”
BackgroundBardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105351 · Cited by 890
Enomoto, A. (2001) · Toxicological Sciences · doi:10.1093/toxsci/59.1.169 · Cited by 728
Liu, G.-H., Qu, J., & Shen, X. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.01.002 · Cited by 697 · cited 1×
“Experiments provided the evidence that the NF-kB p65 subunit and Nrf2 both bind to the same domain of CBP, a well-established coactivator of Nrf2, and that p65 after phosphorylation at Ser276, through a competitive mechanism, suppresses transcription of AREdependent genes by depriving CBP from Nrf2 [26].”
BackgroundTriterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer
Liby, K. T., Yore, M. M., & Sporn, M. B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2129 · Cited by 637 · cited 1×
“There are other molecules, including the triterpenoid CDDO-ethyl amide or RTA 405 [41], with a similar targetbased activity and the same site relative to bardoxolone methyl, but devoid of the major adverse rodent metabolism.”
BackgroundTrends in cardiovascular complications of diabetes
Fox, C. S. (2004) · JAMA · doi:10.1001/jama.292.20.2495 · Cited by 626
When NRF2 Talks, Who's Listening?
Wakabayashi, N., Slocum, S. L., Skoko, J. J., Shin, S., & Kensler, T. W. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3216 · Cited by 595 · cited 4×
“An NF-kB target such as COX-2 was found to cause a reduction of transcription of Nrf2 and antioxidant genes [21].”
BackgroundInfluentialDisruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice
Rangasamy, T., Guo, J., Mitzner, W. A., Roman, J., Singh, A., Fryer, A. D., Yamamoto, M., Kensler, T. W., Tuder, R. M., Georas, S. N., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050538 · Cited by 580 · cited 1×
“Nrf2deficient mice had enhanced susceptibility to pulmonary inflammation [14], acetaminophen hepatotoxicity [15] and neurodegenerative disease [16].”
BackgroundNrf2, a multi‐organ protector?
Lee, J., Li, J., Johnson, D. A., Stein, T. D., Kraft, A. D., Calkins, M. J., Jakel, R. J., & Johnson, J. A. (2005) · The FASEB Journal · doi:10.1096/fj.04-2591hyp · Cited by 532
Therapeutic Potential of Nrf2 Activators in Streptozotocin-Induced Diabetic Nephropathy
Zheng, H., Whitman, S. A., Wu, W., Wondrak, G. T., Wong, P. K., Fang, D., & Zhang, D. D. (2011) · Diabetes · doi:10.2337/db11-0807 · Cited by 507 · cited 2×
“Interestingly, besides antioxidant function, Nrf2 activation negatively regulated TGF-β1, extracellular matrix and p21 expression as shown both in the diabetic kidney and in an in vitromodel of mesangial cells [35].”
BackgroundKEAP1 E3 Ligase-Mediated Downregulation of NF-κB Signaling by Targeting IKKβ
Lee, D.-F., Kuo, H.-P., Liu, M., Chou, C.-K., Xia, W., Du, Y., Shen, J., Chen, C.-T., Huo, L., Hsu, M.-C., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.07.025 · Cited by 399 · cited 1×
“Depletion of Keap1 led to the accumulation and stabilization of IKKβ and to upregulation of NF-kB-dependent genes [31].”
BackgroundLiby, K., Hock, T., Yore, M. M., Suh, N., Place, A. E., Risingsong, R., Williams, C. R., Royce, D. B., Honda, T., Honda, Y., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4539 · Cited by 283
for the ORIENT study investigators, Imai, E., Chan, J. C. N., Ito, S., Yamasaki, T., Kobayashi, F., Haneda, M., & Makino, H. (2011) · Diabetologia · doi:10.1007/s00125-011-2325-z · Cited by 236 · cited 1×
“Moreover, multimodal interventions to afford renoprotection in overt type 2 diabetic nephropathy have given disappointing results, as recently shown, among others, by the ORIENT study of olmesartan [57] and the ALTITUDE study of aliskiren [58], raising the need for alternative therapeutic strategies.”
ResultJin, W., Wang, H., Yan, W., Xu, L., Wang, X., Zhao, X., Yang, X., Chen, G., & Ji, Y. (2008) · Mediators of Inflammation · doi:10.1155/2008/725174 · Cited by 172 · cited 1×
“In addition, Nrf2 knockout mice showed enhanced NF-kB activity and expression of inflammatory genes in response to different insults than the corresponding wild-type mice [28, 29].”
BackgroundMyocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty rats
Fredersdorf, S., Thumann, C., Ulucan, C., Griese, D. P., Luchner, A., Riegger, G. A. J., Kromer, E. P., & Weil, J. (2004) · Cardiovascular Pathology · doi:10.1016/s1054-8807(03)00109-1 · Cited by 115
Ichikawa, T., Li, J., Meyer, C. J., Janicki, J. S., Hannink, M., & Cui, T. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008391 · Cited by 99 · cited 1×
“They instead offered to test in ZDF rats a variant of bardoxolone methyl and RTA 405, the novel synthetic triterpenoid derivative dihydroCDDO-trifluoroethyl amide (dh404) [72] said to be well tolerated by rodents.”
Background
Cited by
Duni, A., Liakopoulos, V., Roumeliotis, S., Peschos, D., & Dounousi, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153711 · Cited by 382
Natural product-derived pharmacological modulators of Nrf2/ARE pathway for chronic diseases
Kumar, H., Kim, I.-S., More, S. V., Kim, B.-W., & Choi, D.-K. (2014) · Nat. Prod. Rep. · doi:10.1039/c3np70065h · Cited by 333
Bao, L., Li, J., Zha, D., Zhang, L., Gao, P., Yao, T., & Wu, X. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2017.11.021 · Cited by 308
Houghton, C. A., Fassett, R. G., & Coombes, J. S. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/7857186 · Cited by 297
Mitochondria Damage and Kidney Disease
Duann, P., & Lin, P.-H. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-55330-6_27 · Cited by 258
Metadata
- Authors
- Zoja, C., Benigni, A., & Remuzzi, G.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-06-11
- Volume
- 29
- Issue
- suppl 1
- Pages
- i19-i24
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2161096223
- Cited by
- 134
- References
- 20
- FWCI
- 4.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.